BioSyent (RX.V) Stock Price

BioSyent Price

TSX·CLOSED
14.50CAD+0.00 (+0.00 %)
Market closed

Revenue has compounded at 22.4% per year over the past 19 years to 35.03 M CAD. Earnings per share have grown at 15.3% per year over the last 19 years. BioSyent's net margin stands at 20.8%, up from 17.0% several years earlier. BioSyent currently offers a dividend yield of about 1.24%. The payout ratio is around 15% of earnings. The dividend has grown at 112.1% per year over the past 2 years. Analysts set a median price target of 16.83 CAD, implying 16.1% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 35% above its 52-week low.

BioSyent stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of BioSyent over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioSyent stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioSyent's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

BioSyent Stock Price History
DateBioSyent Price
7/17/202614.50 CAD
7/16/202614.50 CAD
7/15/202614.60 CAD
7/14/202614.60 CAD
7/13/202614.51 CAD
7/10/202614.60 CAD
7/9/202614.72 CAD
7/8/202614.64 CAD
7/7/202614.42 CAD
7/6/202614.57 CAD
7/3/202614.50 CAD
7/2/202614.55 CAD
6/30/202614.50 CAD
6/29/202614.69 CAD
6/26/202614.05 CAD
6/25/202613.93 CAD
6/24/202614.00 CAD
6/23/202614.04 CAD
6/22/202614.00 CAD
6/19/202613.95 CAD
6/18/202613.95 CAD
6/17/202613.86 CAD
6/16/202614.00 CAD
6/15/202613.95 CAD
6/12/202613.89 CAD
6/11/202614.00 CAD
6/10/202614.00 CAD
6/9/202613.70 CAD
6/8/202613.85 CAD
6/5/202613.70 CAD
6/4/202614.00 CAD
6/3/202613.95 CAD
6/2/202613.83 CAD
6/1/202614.05 CAD
5/29/202613.96 CAD
5/28/202614.00 CAD
5/27/202613.91 CAD
5/26/202613.95 CAD
5/25/202613.76 CAD
5/22/202613.70 CAD
5/21/202613.86 CAD
5/20/202614.00 CAD
5/19/202614.27 CAD
5/15/202614.44 CAD
5/14/202614.43 CAD
5/13/202614.55 CAD
5/12/202614.65 CAD
5/11/202614.65 CAD
5/8/202614.70 CAD
5/7/202614.64 CAD
5/6/202614.60 CAD
5/5/202614.60 CAD
5/4/202614.40 CAD
5/1/202614.31 CAD
4/30/202614.60 CAD
4/29/202614.61 CAD
4/28/202614.50 CAD
4/27/202614.85 CAD
4/24/202614.75 CAD
4/23/202615.00 CAD
4/22/202615.00 CAD
4/21/202614.90 CAD
4/20/202615.25 CAD
4/17/202614.80 CAD
4/16/202614.84 CAD
4/15/202614.90 CAD
4/14/202614.88 CAD
4/13/202614.95 CAD
4/10/202615.25 CAD
4/9/202615.12 CAD
4/8/202614.63 CAD
4/7/202614.41 CAD
4/6/202614.60 CAD
4/2/202614.87 CAD
3/27/202614.70 CAD
3/26/202614.80 CAD
3/25/202614.61 CAD
3/24/202614.70 CAD
3/23/202615.15 CAD
3/20/202615.35 CAD
3/19/202615.50 CAD
3/18/202615.50 CAD
3/17/202615.20 CAD
3/16/202615.70 CAD
3/13/202615.70 CAD
3/12/202615.70 CAD
3/11/202615.50 CAD
3/10/202615.50 CAD
3/9/202615.56 CAD
3/6/202615.70 CAD
3/5/202615.50 CAD
3/4/202615.65 CAD
2/26/202615.27 CAD
2/25/202615.80 CAD
2/24/202615.80 CAD
2/23/202614.66 CAD
2/20/202614.88 CAD
2/19/202615.06 CAD
2/18/202614.80 CAD
2/17/202614.80 CAD
2/13/202614.93 CAD
2/12/202614.60 CAD
2/11/202614.60 CAD
2/10/202614.51 CAD
2/9/202613.76 CAD
2/6/202612.73 CAD
2/5/202613.80 CAD
2/4/202614.42 CAD
2/3/202612.55 CAD
2/2/202612.56 CAD
1/30/202612.50 CAD
1/29/202612.85 CAD
1/28/202612.90 CAD
1/27/202613.07 CAD
1/26/202613.39 CAD
1/23/202613.25 CAD
1/22/202613.30 CAD
1/21/202612.84 CAD
1/20/202612.85 CAD
1/19/202612.70 CAD
1/16/202612.95 CAD
1/15/202613.10 CAD
1/14/202613.00 CAD
1/13/202613.25 CAD
1/12/202612.97 CAD
1/9/202612.87 CAD
1/8/202612.87 CAD
1/7/202612.61 CAD
1/6/202612.56 CAD
1/5/202612.49 CAD
1/2/202612.76 CAD
12/31/202512.73 CAD
12/30/202512.89 CAD
12/29/202512.90 CAD
12/24/202512.80 CAD
12/23/202512.50 CAD
12/22/202512.30 CAD
12/19/202512.25 CAD
12/18/202512.25 CAD
12/17/202511.95 CAD
12/16/202512.10 CAD
12/15/202512.02 CAD
12/12/202512.15 CAD
12/11/202512.05 CAD
12/10/202511.82 CAD
12/9/202512.10 CAD
12/8/202512.24 CAD
12/5/202512.18 CAD
12/4/202512.03 CAD
12/2/202511.83 CAD
12/1/202512.15 CAD
11/28/202512.14 CAD
11/27/202512.12 CAD
11/26/202511.63 CAD
11/25/202510.90 CAD
11/24/202510.85 CAD
11/21/202510.76 CAD
11/20/202510.72 CAD
11/19/202510.75 CAD
11/18/202510.76 CAD
11/17/202510.99 CAD
11/14/202511.00 CAD
11/13/202510.90 CAD
11/12/202510.75 CAD
11/11/202510.71 CAD
11/10/202510.84 CAD
11/7/202510.97 CAD
11/6/202510.77 CAD
11/5/202510.80 CAD
11/4/202510.88 CAD
11/3/202510.90 CAD
10/31/202511.00 CAD
10/30/202510.80 CAD
10/29/202511.15 CAD
10/28/202511.00 CAD
10/27/202511.06 CAD
10/24/202511.20 CAD
10/23/202511.21 CAD
10/22/202511.15 CAD
10/21/202511.00 CAD
10/20/202511.00 CAD
10/17/202511.00 CAD
10/16/202511.20 CAD
10/15/202511.25 CAD
10/14/202511.57 CAD
10/10/202511.55 CAD
10/9/202511.70 CAD
10/8/202511.75 CAD
10/7/202511.65 CAD
10/6/202511.72 CAD
10/3/202511.98 CAD
10/2/202511.56 CAD
10/1/202511.56 CAD
9/30/202511.54 CAD
9/29/202511.78 CAD
9/25/202511.76 CAD
9/24/202511.81 CAD
9/23/202511.70 CAD
9/22/202511.65 CAD
9/19/202511.70 CAD
9/18/202512.00 CAD
9/17/202512.00 CAD
9/16/202512.00 CAD
9/15/202511.87 CAD
9/12/202511.89 CAD
9/11/202511.82 CAD
9/10/202511.82 CAD
9/9/202512.00 CAD
9/8/202512.00 CAD
9/5/202511.81 CAD
9/4/202512.04 CAD
9/3/202511.97 CAD
9/2/202512.00 CAD
8/29/202512.07 CAD
8/28/202512.10 CAD
8/27/202511.74 CAD
8/26/202512.05 CAD
8/25/202512.01 CAD
8/22/202512.01 CAD
8/21/202511.55 CAD
8/20/202511.50 CAD
8/19/202511.35 CAD
8/18/202511.30 CAD
8/15/202511.40 CAD
8/14/202511.33 CAD
8/13/202511.38 CAD
8/12/202511.40 CAD
8/11/202511.40 CAD
8/8/202511.44 CAD
8/7/202511.45 CAD
8/6/202511.53 CAD
8/5/202511.45 CAD
8/1/202511.38 CAD
7/30/202511.31 CAD
7/29/202511.15 CAD
7/28/202511.59 CAD
7/25/202511.59 CAD
7/24/202511.44 CAD
7/23/202511.55 CAD
7/22/202511.68 CAD
7/21/202511.40 CAD
Access this data via the Eulerpool API
Get Free API Key

BioSyent Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
22.33 M CAD
5.13 M CAD
3.80 M CAD
Jan 1, 2021
28.62 M CAD
8.25 M CAD
6.28 M CAD
Jan 1, 2022
27.93 M CAD
7.01 M CAD
5.46 M CAD
Jan 1, 2023
31.59 M CAD
7.53 M CAD
6.46 M CAD
Jan 1, 2024
35.03 M CAD
9.06 M CAD
7.27 M CAD
Jan 1, 2025 (e)
44.47 M CAD
0.00 CAD
8.91 M CAD
Jan 1, 2026 (e)
45.80 M CAD
0.00 CAD
10.48 M CAD
Jan 1, 2027 (e)
49.47 M CAD
0.00 CAD
11.44 M CAD

BioSyent Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 20, 2026, 9:04 AM
 
REVENUEM CAD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM CAD
EBITM CAD
EBIT MARGIN%
NET INCOMEM CAD
NET INCOME GROWTH%
DIV.CAD
DIV. GROWTH%
SHARESM
20122013201420152016201720182019202020212022202320242025e2026e2027e
5.007.0012.0015.0017.0020.0021.0021.0022.0028.0027.0031.0035.0044.0045.0049.00
150.0040.0071.4325.0013.3317.655.00–4.7627.27-3.5714.8112.9025.712.278.89
60.0085.7175.0080.0082.3575.0076.1976.1977.2778.5781.4880.6577.1477.1477.1477.14
3.006.009.0012.0014.0015.0016.0016.0017.0022.0022.0025.0027.0033.9434.7137.80
1.002.004.005.005.006.006.006.005.008.007.007.009.00–––
20.0028.5733.3333.3329.4130.0028.5728.5722.7328.5725.9322.5825.71–––
1.001.003.003.004.005.005.004.003.006.005.006.007.008.0010.0011.00
––200.00–33.3325.00–-20.00-25.00100.00-16.6720.0016.6714.2925.0010.00
––––––––––0.160.160.180.200.220.25
––––––––––––12.5011.1110.0013.64
14.1614.4014.3614.4414.5114.5914.5413.9513.0912.8712.5412.1711.8111.8111.8111.81
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales BioSyent generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioSyent retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioSyent's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares BioSyent has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioSyent's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

BioSyent stock margins

The BioSyent margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioSyent. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioSyent.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
78.02 %
22.95 %
16.99 %
Jan 1, 2021
79.10 %
28.82 %
21.95 %
Jan 1, 2022
81.85 %
25.11 %
19.55 %
Jan 1, 2023
81.03 %
23.85 %
20.45 %
Jan 1, 2024
79.52 %
25.88 %
20.75 %
Jan 1, 2025 (e)
79.52 %
0.00 %
20.04 %
Jan 1, 2026 (e)
79.52 %
0.00 %
22.88 %
Jan 1, 2027 (e)
79.52 %
0.00 %
23.13 %

BioSyent Stock Revenue, EBIT, Earnings per Share

The BioSyent earnings per share therefore indicates how much revenue BioSyent has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
1.71 CAD
0.39 CAD
0.29 CAD
Jan 1, 2021
2.22 CAD
0.64 CAD
0.49 CAD
Jan 1, 2022
2.23 CAD
0.56 CAD
0.44 CAD
Jan 1, 2023
2.60 CAD
0.62 CAD
0.53 CAD
Jan 1, 2024
2.97 CAD
0.77 CAD
0.62 CAD
Jan 1, 2025 (e)
3.77 CAD
0.00 CAD
0.75 CAD
Jan 1, 2026 (e)
3.88 CAD
0.00 CAD
0.89 CAD
Jan 1, 2027 (e)
4.19 CAD
0.00 CAD
0.97 CAD

BioSyent business model & stock analysis

Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market.

BioSyent SWOT Analysis

Strengths

Biosyent Inc. has several key strengths that contribute to its competitive advantage and success in the market. These include:

  • Strong product portfolio: Biosyent offers a diverse range of pharmaceutical and healthcare products, which enables it to cater to various market segments and meet the needs of a broad customer base.
  • Established market presence: With years of experience and a solid reputation, Biosyent has established itself as a trusted and reliable provider of high-quality pharmaceuticals in the industry.
  • Strategic partnerships: The company has formed strategic partnerships with key distributors and healthcare professionals, allowing it to effectively reach its target market and expand its customer base.
  • Financial stability: Biosyent has a strong financial position, well-managed cash flow, and a robust revenue stream, which provides stability and enables continued investment in research and development.

Weaknesses

Despite its strengths, Biosyent Inc. also has certain weaknesses that pose challenges and areas for improvement:

  • Limited global reach: The company's operations are primarily focused on the Canadian market, which limits its exposure to international opportunities and potential for growth.
  • Dependence on key products: Biosyent's success is largely dependent on a few core products, making it vulnerable to market fluctuations and increased competition in those specific markets.
  • Relatively small size: As a smaller pharmaceutical company, Biosyent may face challenges in terms of resources, market influence, and the ability to compete with larger industry players.

Opportunities

Several opportunities exist for Biosyent Inc. to capitalize on and further strengthen its market position:

  • Expansion into new markets: Biosyent can explore potential expansion into international markets, leveraging its strong product portfolio to cater to new customer segments and increase its global footprint.
  • Growing healthcare industry: The increasing demand for healthcare products and services presents an opportunity for Biosyent to introduce new products and tap into emerging market trends.
  • Strategic collaborations: By establishing partnerships with research institutions and pharmaceutical companies, Biosyent can enhance its research and development capabilities and accelerate product innovation.

Threats

Biosyent Inc. faces certain threats that may impact its growth and market position:

  • Market competition: The pharmaceutical industry is highly competitive, and Biosyent faces competition from both established players and new entrants, which can put pressure on pricing and market share.
  • Regulatory challenges: Stringent regulations and compliance requirements in the pharmaceutical industry can pose challenges for Biosyent, particularly in terms of product development and approvals.
  • Economic and market volatility: Uncertain economic conditions and market fluctuations can impact consumer spending, healthcare budgets, and overall demand for pharmaceutical products.

BioSyent Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

BioSyent historical P/E ratio, EBIT multiple, and P/S ratio

BioSyent annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

BioSyent shares outstanding

The number of shares of BioSyent was 11.81 M in 2025. This indicates how many shares BioSyent is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
13.09 M Stocks
Jan 1, 2021
12.87 M Stocks
Jan 1, 2022
12.54 M Stocks
Jan 1, 2023
12.17 M Stocks
Jan 1, 2024
11.81 M Stocks
Jan 1, 2025 (e)
11.81 M Stocks
Jan 1, 2026 (e)
11.81 M Stocks
Jan 1, 2027 (e)
11.81 M Stocks

BioSyent Dividend History

5 years of dividend payments · 3 consecutive increases

YearAnnual DividendYoY ChangePayments
20260.06CADYTD—1×
Feb 27, 20260.06CAD↑ 10.0%1/1
20250.20CAD↑ 11.1%4×
Feb 28, 20250.05CAD↑ 11.1%1/4
May 30, 20250.05CAD 0.0%2/4
Aug 29, 20250.05CAD 0.0%3/4
Nov 28, 20250.05CAD 0.0%4/4
20240.18CAD↑ 12.5%4×
20230.16CAD↑ 300.0%4×
20220.04CAD—1×

BioSyent dividend history and estimates

In 2025, BioSyent paid a dividend amounting to 0.20 CAD. Dividend means that BioSyent distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2022 (e)
0.04 CAD
0.12 CAD
Jan 1, 2023
0.16 CAD
0.00 CAD
Jan 1, 2024
0.18 CAD
0.00 CAD
Jan 1, 2025
0.20 CAD
0.00 CAD
Jan 1, 2026 (e)
0.00 CAD
0.22 CAD
Jan 1, 2027 (e)
0.00 CAD
0.25 CAD

BioSyent dividend payout ratio

In 2025, BioSyent had a payout ratio of 26.50%. The payout ratio indicates the percentage of the company's profits that BioSyent distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
17.98 %
Jan 1, 2021
17.98 %
Jan 1, 2022
9.19 %
Jan 1, 2023
30.14 %
Jan 1, 2024
14.62 %
Jan 1, 2025 (e)
26.50 %
Jan 1, 2026 (e)
25.20 %
Jan 1, 2027 (e)
25.80 %

Current BioSyent forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
22.22 %
Buy85.71 % (6)
Hold14.29 % (1)
Sell0.00 % (0)
12M Price Target
16.83
Last Price
14.50
Currency
CAD
12M Return Potential
16.07 %
LTM Return
0 %

BioSyent Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
3/19/20240.10CAD8.67 MCAD2023 Q4
3/7/20230.12CAD7.21 MCAD2022 Q4
11/8/20220.13CAD7.10 MCAD2022 Q3
8/23/20220.14CAD7.61 MCAD2022 Q2
5/18/20220.11CAD7.10 MCAD2022 Q1
3/8/20220.11CAD7.00 MCAD2021 Q4
11/18/20210.10CAD7.00 MCAD2021 Q3
8/25/20210.10CAD5.79 MCAD2021 Q2
5/27/20210.09CAD6.19 MCAD2021 Q1
3/17/20210.08CAD5.58 MCAD2020 Q4

BioSyent shareholder structure

% Name
14.64605%
Goehrum (René Christopher)
Goehrum (René Christopher)
9.17005%
FAX Investments, Inc.
FAX Investments, Inc.
4.23445%
Aquiam Partners, Ltd.
Aquiam Partners, Ltd.
1.84985%
Van Berkom & Associates Inc.
Van Berkom & Associates Inc.
1.80292%
Grandeur Peak Global Advisors, LLC
Grandeur Peak Global Advisors, LLC
1.32357%
Lockhard (Peter Douglas)
Lockhard (Peter Douglas)

BioSyent Executives and Management Board

RG

Mr. Rene Goehrum

(66)

Chairman of the Board, President and Chief Executive Officer · since 1996

Compensation761,523.00 CAD
RM

Mr. Robert March

Chief Financial Officer, Vice President - Finance

Compensation356,750.00 CAD
JM

Mr. Joost Van Der Mark

Vice President- Corporate Development

Compensation348,580.00 CAD
NA

Mr. Navid Ashrafi

Director- Medical and Regulatory Affairs

Compensation264,585.00 CAD
KW

Mr. Kevin Wilson

Vice President - Sales

Compensation255,093.00 CAD

BioSyent Supply Chain

BioSyent Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#Name1M3M6M1Y2YTrend
1
Mithra Pharmaceuticals
Supplier
0.81
-0.22
-0.65
-0.60
—
2
Photocure
Supplier
0.78
0.86
0.82
-0.16
—
3
AFT Pharmaceuticals
Supplier
0.25
-0.04
-0.54
-0.56
—

Frequently asked questions about BioSyent

The business model of Biosyent Inc is focused on acquiring or in-licensing pharmaceutical and healthcare products. The company identifies niche markets with unmet medical needs and seeks regulatory approval to provide branded pharmaceuticals or health products that address those needs. Biosyent Inc aims to improve patient outcomes by offering innovative and effective treatment options in areas such as cardiovascular health, dermatology, neurology, and pediatrics. By partnering with established companies or acquiring the rights to specific products, Biosyent Inc brings affordable and quality medicines to market, providing patients with improved access to vital healthcare solutions.

All fundamentals and in-depth analysis of BioSyent

Our stock analysis for BioSyent stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioSyent. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

BioSyent Stock
BioSyent Revenue→
BioSyent Stock
BioSyent Net Income→
BioSyent Stock
BioSyent P/E→
BioSyent Stock
BioSyent P/S→
BioSyent Stock
BioSyent EBIT→
BioSyent Stock
BioSyent Dividend→
BioSyent Stock
BioSyent Directors Dealings→
BioSyent Stock
BioSyent Stocks→
BioSyent Stock
BioSyent Market capitalization→
BioSyent Stock
BioSyent Debt→
BioSyent Stock
BioSyent Liabilities→
BioSyent Stock
BioSyent Equity→
BioSyent Stock
BioSyent AAQS→
BioSyent Stock
BioSyent Employees→
BioSyent Stock
BioSyent ROE→
BioSyent Stock
BioSyent ROA→
BioSyent Stock
BioSyent ROCE→
BioSyent Stock
BioSyent News→
BioSyent Stock
BioSyent Analyst Price Targets→

Health Stocks

BiosynexBiostem TechnologiesBioteBiostaxBiotechnology AssetsBiostar PharmaceuticalsBiotequeBiosino Bio-Technology and ScienceBiotonBiosergenBioToxTech CoBiosenicAll Stocks A–Z →